Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences (Q40931968)

25 September 2017

Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences (English)

1 reference

25 September 2017

G J Moyle

1

1 reference

25 September 2017

1 August 1996

1 reference

25 September 2017

1 reference

25 September 2017

52

1 reference

25 September 2017

2

1 reference

25 September 2017

168-185

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199652020-00002

25 September 2017

0 references

cites work

Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors

1 reference

12 December 2020

Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture

1 reference

12 December 2020

Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor

1 reference

12 December 2020

pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo

1 reference

12 December 2020

Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance

1 reference

12 December 2020

Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase

1 reference

12 December 2020

Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine

1 reference

12 December 2020

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

1 reference

12 December 2020

Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.

1 reference

12 December 2020

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

1 reference

12 December 2020

HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase

1 reference

12 December 2020

Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy

1 reference

12 December 2020

Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera

1 reference

12 December 2020

Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy

1 reference

12 December 2020

A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors

1 reference

12 December 2020

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

12 December 2020

Nonhomogeneous distribution of human immunodeficiency virus type 1 proviruses in the spleen

1 reference

12 December 2020

Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients

1 reference

12 December 2020

Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study

1 reference

12 December 2020

Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine

1 reference

12 December 2020

Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture

1 reference

12 December 2020

Current knowledge and future prospects for the use of HIV protease inhibitors

1 reference

12 December 2020

Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression

1 reference

12 December 2020

Clinical correlates of in vitro HIV-1 resistance ot zidovudine. Results of the Multicentre Canadian AZT Trial

1 reference

12 December 2020

Genomic variation of human immunodeficiency virus type 1 (HIV-1): molecular analyses of HIV-1 in sequential blood samples and various organs obtained at autopsy.

1 reference

12 December 2020

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects

1 reference

12 December 2020

Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.

1 reference

12 December 2020

Influence of emergence of viral resistance on HIV treatment choice

1 reference

12 December 2020

Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials

1 reference

12 December 2020

HIV-1 Drug Resistance: Molecular Pathogenesis and Laboratory Monitoring

1 reference

12 December 2020

Characterization of genetic variation and 3'-azido-3'-deoxythymidine- resistance mutations of human immunodeficiency virus by the RNase A mismatch cleavage method

1 reference

12 December 2020

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Human immunodeficiency virus type 1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"- oxathiole-2",2"-dioxide)-purine analogues show a resistance spectrum that is different from that of the human imm

1 reference

12 December 2020

Study of human immunodeficiency virus resistance to 2'-3'-dideoxyinosine and zidovudine in sequential isolates from pediatric patients on long-term therapy

1 reference

12 December 2020

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

1 reference

12 December 2020

Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus.

1 reference

12 December 2020

HIV treatment choice based on resistance patterns.

1 reference

12 December 2020

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

12 December 2020

HIV-1, the brain, and combination therapy

1 reference

12 December 2020

Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy

1 reference

12 December 2020

Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study

1 reference

12 December 2020

HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy

1 reference

12 December 2020

Extensive variation of human immunodeficiency virus type-1 in vivo

1 reference

12 December 2020

Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. The VA Cooperative Study Group

1 reference

12 December 2020

Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors

1 reference

12 December 2020

Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance

1 reference

12 December 2020

Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates

1 reference

12 December 2020

Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group

1 reference

12 December 2020

Genetic diversity and evolution of retroviruses.

1 reference

12 December 2020

Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes

1 reference

12 December 2020

Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro

1 reference

12 December 2020

Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease

1 reference

12 December 2020

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

1 reference

12 December 2020

Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents

1 reference

12 December 2020

Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.

1 reference

12 December 2020

A nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitors

1 reference

12 December 2020

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

1 reference

12 December 2020

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

1 reference

12 December 2020

Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs

1 reference

12 December 2020

In vivo comparison of zidovudine resistance mutations in blood and CSF of HIV-1-infected patients.

1 reference

12 December 2020

A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients

1 reference

12 December 2020

3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers

1 reference

12 December 2020

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

12 December 2020

Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization

1 reference

12 December 2020

Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins

1 reference

12 December 2020

HIV-1 sensitivity to zidovudine and clinical outcome in children

1 reference

12 December 2020

Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine

1 reference

12 December 2020

Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients.

1 reference

12 December 2020

Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells.

1 reference

12 December 2020

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

1 reference

12 December 2020

Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase

1 reference

12 December 2020

Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959.

1 reference

12 December 2020

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

1 reference

12 December 2020

Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay

1 reference

12 December 2020

Individualisation of HIV therapy: the clinician's perspective

1 reference

12 December 2020

Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences

1 reference

12 December 2020

Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro

1 reference

12 December 2020

Antiviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions

1 reference

12 December 2020

Zidovudine induces the expression of cellular resistance affecting its antiviral activity.

1 reference

12 December 2020

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

1 reference

12 December 2020

Failure of antiretroviral therapy: role of viral and cellular factors

1 reference

12 December 2020

Zidovudine-resistant variants of HIV-1 in brain.

1 reference

12 December 2020

A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group

1 reference

12 December 2020

Zidovudine-resistant and -sensitive HIV-1 isolates from patients on drug therapy: in vitro studies evaluating level of replication-competent viruses and cytopathogenicity

1 reference

12 December 2020

Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy

1 reference

12 December 2020

Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

1 reference

12 December 2020

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

1 reference

12 December 2020

Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine

1 reference

12 December 2020

Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein.

1 reference

12 December 2020

Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team

1 reference

12 December 2020

Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor

1 reference

12 December 2020

Identification of a novel human immunodeficiency virus strain cytopathic to megakaryocytic cells.

1 reference

12 December 2020

Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection.

1 reference

12 December 2020

The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

1 reference

12 December 2020

Characterization of HIV isolates arising after prolonged zidovudine therapy

1 reference

12 December 2020

Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex.

1 reference

12 December 2020

Two-Drug Combinations of Zidovudine, Didanosine, and Recombinant Interferon- A Inhibit Replication of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Synergistically In Vitro

1 reference

12 December 2020

Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy

1 reference

12 December 2020

Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection

1 reference

12 December 2020

Active human immunodeficiency virus protease is required for viral infectivity

1 reference

12 December 2020

Structures of DNA and RNA polymerases and their interactions with nucleic acid substrates

1 reference

12 December 2020

Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not.

1 reference

12 December 2020

Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group

1 reference

12 December 2020

Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.

1 reference

12 December 2020

Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity

1 reference

12 December 2020

Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy

1 reference

12 December 2020

HIV-1 Reverse Transcriptase Codon 215 Mutation and Clinical Outcome in Children Treated with Zidovudine

1 reference

12 December 2020

Development and significance of zidovudine resistance in children infected with human immunodeficiency virus

1 reference

12 December 2020

Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Loviride Collaborative Study Group

1 reference

12 December 2020

Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene.

1 reference

12 December 2020

Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus

1 reference

12 December 2020

Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.

1 reference

12 December 2020

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

12 December 2020

Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs

1 reference

12 December 2020

Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy

1 reference

12 December 2020

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor

1 reference

12 December 2020

Detection of Mutations Associated with Zidovudine Resistance in Human Immunodeficiency Virus by Use of the Polymerase Chain Reaction

1 reference

12 December 2020

Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance.

1 reference

12 December 2020

10.2165/00003495-199652020-00002

Identifiers

DOI

1 reference

PubMed ID

8841736

Dimensions Publication ID

25 September 2017

0 references

1 reference

PubMed ID

8841736